Aspirin resistance and genetic polymorphisms

Journal of Thrombosis and Thrombolysis

Volumn 14, Issue 1, 2002, Pages 51-58

  Gandhi, Pritesh J ^a   Cambria Kiely, Josie A ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Aspirin; Cyclooxygenase; Ischemic events; Myocardial infarction; Platelets; Polymorphisms

Indexed keywords

ACETYLSALICYLIC ACID; ALLOANTIGEN; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLYCOPROTEIN IIIA; HEPARIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE; THROMBOCYTE SPECIFIC ALLOANTIGEN 1; THROMBOCYTE SPECIFIC ALLOANTIGEN 2; TICLOPIDINE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; WARFARIN;

ALLELE; ANTICOAGULATION; BLEEDING TIME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY STENT; DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MEDICAL LITERATURE; NONHUMAN; POSTOPERATIVE THROMBOSIS; PREDICTION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SERUM; STATISTICAL ANALYSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0037288750     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022066305399     Document Type: Review

References (51)

1. International SNP Map Working Group. A map of the human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-933.
2. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986;2:533-537.
3. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-505.
4. Jansson JK, Nilsson TK, Johnson O. von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-355.
5. Hamsten A, De Faire U, Walldius G, et al. Plasminogen activatory inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
6. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994;343:940-943.
7. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance. J Thromb and Thrombol 2002;13:49-56.
8. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. NEJM 2001;345:494-502.
9. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533.
10. Vu TKH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-1068.
11. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998;394:690-694.
12. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994;31:229-239.
13. Topol EJ, Byzova TV, Plow E. Platelet GPIIb/IIIa blockers. Lancet 1999;353:227-231.
14. The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
15. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
16. The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
17. Kunicki TJ, Newman PJ. The molecular biology of human platelet proteins. Blood 1992;80:1396-1404.
18. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;1011206-1011218.
19. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. NEJM 2001;354:433-442.
20. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988;85:1412-1416.
21. DeWitt DL, El-Harith EA, Kraemer SA, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990;265:5192-5198.
22. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975;72:3073-3076.
23. Catella-Lawson F, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. NEJM 2001;345:1809.
24. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. Federation of American Societies for Experimental Biology Journal 1991;5:2304-2312.
25. Guo Q, Kulmacz RJ. Distinct influences of carboxyl terminal segment structure on function in the two isoforms of prostaglandin H synthase. Arch Biochem Biophys 2000;384:269-279.
26. Ren Y, Loosemitchell DS, Kulmacz RJ. Prostaglandin H synthase-1: Evaluation of c-terminus function. Arch Biochem Biophys 1995;316:751-757.
27. Karim S, Habib A, Levy-Toledano S, et al. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996;271:12042-12048.
28. Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicol 1998;38:97-120.
29. Okahara K, Sun B, Kambayashi J. Up-regulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:1922.
30. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350.
31. Weber AA, Zimmermann KM, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.
32. Caughey GF, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: Selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001;167:2831-2838.
33. Eikelboom JW, Hirsh J, Weit JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002:105:1650-1655.
34. Newman PJ. Platelet alloantigens: Cardiovascular as well as immunological risk factors? Lancet 1997;349:370-371.
35. Nurden AT. Platelet glycoprotein IIIa polymorphism and coronary thrombosis. Lancet 1997;350:1189-1191.
36. Michaelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa PLA polymorphisms display different sensitivities to agonists. Circulation 2000;101:1013-1018.
37. Andrioli G, Minuz P, Solero P, et al. Deffective platelet response to arachidonic acid and thromboxane A(2) in subjects with PL(A2) polymorphism of beta(3) subunit glycoprotein IIIa. British Journal of Haematology 2000;110:911-918.
38. Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W. Relationship between bleeding time, aspirin and the PLA1/A2 polymorphism of platelet glycoprotein IIIa. British Journal of Haematology 2000;110:965-967.
39. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-1094.
40. Walter DH, Schachinger V, Eisner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and the risk of coronary stent thrombosis. Lancet 1997;350:1217-1219.
41. Kastrati A, Schomig A, Seyfarth M, et al. PLA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005-1010.
42. Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet PLA polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bβ 448 polymorphism with myocardial infarction and extent coronary artery disease. Circulation 1997;96:1424-1431.
43. Ardissino PM, Mannucci PM, Merlini PA, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999;94:46-51.
44. Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation (letter). Lancet 1999;353:982-983.
45. Dominguez-Jimenez C, Diaz-Gonzalez F, Gonzalez-Alvaro I, Cesar JM, Sanchez-Madrid F. Prevention of αIIbβ3 activation by non-steroidal antiinflammatory drugs. Federation of European Biochemical Socities Letters 1999;446:318-322.
46. Ridker PM, et al. PL(A1/A2) polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997;349:385-388.
47. Herrmann SM, Poirier O, Marques-Vidal P, et al. The Leu 33/Pro polymorphism (PLA1/PLA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost 1997;77:1179-1181.
48. Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin a2 b1 activity on human platelets. Blood 1993;82:2693.
49. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 1997;89:1939-1943.
50. Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction. Lancet 1999;353:351-354.
51. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. NEJM 1997;336:1276-1282.